Stephen G. Dilly
2016 - Aimmune Therapeutics
In 2016, Stephen G. Dilly earned a total compensation of $3.3M as Chief Executive Officer at Aimmune Therapeutics, a 9% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $220,000 |
|---|---|
| Option Awards | $2,675,832 |
| Salary | $440,000 |
| Total | $3,335,832 |
Dilly received $2.7M in option awards, accounting for 80% of the total pay in 2016.
Dilly also received $220K in non-equity incentive plan and $440K in salary.
Rankings
In 2016, Stephen G. Dilly's compensation ranked 2,810th out of 14,075 executives tracked by ExecPay. In other words, Dilly earned more than 80.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,810 out of 14,075 | 80th |
Division Manufacturing | 975 out of 5,488 | 82nd |
Major group Chemicals And Allied Products | 288 out of 1,900 | 85th |
Industry group Drugs | 210 out of 1,543 | 86th |
Industry Pharmaceutical Preparations | 162 out of 1,173 | 86th |
Source: SEC filing on April 11, 2018.
Dilly's colleagues
We found three more compensation records of executives who worked with Stephen G. Dilly at Aimmune Therapeutics in 2016.